Hand rejuvenation: filler vs fat grafting vs skin treatment

Hand filler, autologous fat grafting, and surface treatments solve different problems. Certain named fillers have FDA-approved indications for dorsal-hand volume loss; fat grafting transfers a person’s own harvested tissue through a surgical procedure; lasers, light devices, and peels address selected pigment, vascular, or texture findings rather than replacing missing volume. Start by mapping the visible concern to tissue depth, then verify the exact product, procedure, evidence, operator, and recovery plan.¹²³⁴

“Aged hands” is not a single diagnosis. Tendon and vein visibility, thin subcutaneous tissue, brown spots, rough texture, visible vessels, laxity, scars, and joint or skin disease can coexist. One product cannot be assumed to treat them all.

Match the modality to the layer

The distinction prevents a common sales shortcut: showing veins or tendons, calling that “crepey skin,” and recommending only a surface procedure—or treating pigment as though more filler will erase it. Standardized photographs under the same lighting can help separate shadow from true color or texture change.

A hand indication belongs to the exact filler

FDA filler approval is product-, anatomy-, plane-, population-, and indication-specific. The Radiesse and Restylane Lyft records cited here include hand indications, but that does not turn every hyaluronic-acid, calcium-hydroxylapatite, biostimulatory, or compounded injectable into an approved hand product.¹²³

Ask for the finished product name, manufacturer, label, lot, expiration, syringe count, intended plane, treated zone, and whether the proposed use matches the approved record. Keep the implant card or treatment record. “FDA-approved ingredient” and “FDA-approved filler for hands” are not equivalent claims.

Hands also have dense visible anatomy and constant movement. The response plan should identify who evaluates disproportionate pain, blanching, color change, numbness, weakness, marked swelling, infection concern, or skin breakdown and what product-specific resources are available. Do not accept “dissolvable” as a complete emergency plan; that term applies only to certain materials and does not replace timely assessment.

Fat grafting is a tissue-transfer operation

Autologous hand fat grafting requires a donor area, harvest, processing, placement, dressings, follow-up, and records for both sites. It is not an FDA-approved filler and should not be sold as an approved “stem-cell treatment.” The systematic review found encouraging reported outcomes but substantial variation in technique and limited long-term evidence across a small literature base.⁴

Compare donor-site burden, anesthesia, operating setting, processing method, placement plan, swelling, activity limits, possible irregularity or fat necrosis, expected uncertainty in retained volume, and the plan if a repeat procedure is considered. A universal permanence percentage is not defensible across techniques and patients.

The value of fat is not simply “natural versus synthetic.” It may offer broader tissue availability and avoids a manufactured filler implant, but it also creates a second procedural site and a less reversible volume decision. A filler plan can be more bounded by syringe and product, yet still carries injection-specific risks and may require future maintenance.

Skin treatment needs its own device or formula record

“Laser hand rejuvenation” can refer to pigment-targeting light, vascular treatment, fractional resurfacing, or another device pathway. “Peel” can describe different chemicals, concentrations, contact times, and intended depths. Record the exact device or formulation, indication, treated finding, test-spot logic when used, skin preparation, eye protection, aftercare, sun plan, and response to delayed pigment change.

FDA notes that filler use with neuromodulators or other treatments has not been evaluated in controlled clinical studies.¹ The broader hand-rejuvenation literature is also dominated by small or noncomparative studies.⁵ Neither point makes every sequence prohibited; it means a package offer is not proof of established combination safety. The plan should explain order, interval, healing gate, and which clinician owns a complication that crosses components.

Compare the plan in five passes

1. 1. Name the dominant deficit Separate dorsal volume loss from pigment, visible vessels, rough texture, laxity, scars, and a finding that first needs medical evaluation.
2. 2. Match one endpoint to each component Require a specific measure for volume, pigment, texture, or another target rather than one global rejuvenation promise.
3. 3. Verify product and procedure status Check the exact filler indication, or document fat harvest and processing, or identify the exact skin device or formulation.
4. 4. Design sequencing and recovery Show why components are same-day or staged, what healing is required, and which activities or hand use are affected.
5. 5. Preserve future options Keep product lots, operative notes, device settings, photographs, adverse-event records, and the maintenance or revision agreement.

The most useful consultation does not begin with a package. It identifies the hand’s volume and surface findings separately, then assigns each proposed intervention a verifiable product record, bounded purpose, safety plan, and decision date.